重新审视分化型甲状腺癌全甲状腺切除术的肿瘤大小阈值
本研究纳入2008至2017年接受甲状腺切除术的771例分化型甲状腺癌患者,分析需行补充甲状腺切除术的相关因素。在初始适合腺叶切除的616例中,273例(44%)需补充切除;微小癌与1-4cm肿瘤的比例分别为18%和57%。肿瘤大小≥1.1cm预测准确性最高,肿瘤大小和BRAF V600E突变是独立预测因素。
要点
- 术前适合腺叶切除的分化型甲状腺癌患者中44%存在中危病理特征需补充切除。
- 微小癌需补充切除比例18%,1-4cm肿瘤为57%。
- 肿瘤大小≥1.1cm预测需补充切除的准确性最高。
核心结论
- 相当部分术前适合腺叶切除的分化型甲状腺癌患者术后发现中危病理特征,需纳入术前共享决策。
研究设计与样本
- 回顾性队列研究,纳入2008至2017年连续接受甲状腺切除术的分化型甲状腺癌患者771例。
主要发现
- 771例中155例(20%)有明确全甲状腺切除指征。
- 初始适合腺叶切除的616例中273例(44%)需补充甲状腺切除术。
- 微小癌需补充切除比例为18%,1-4cm肿瘤为57%。
- 肿瘤大小≥1.1cm预测需补充切除的准确性最高。
- 多因素logistic回归显示肿瘤大小和BRAF V600E突变是需补充切除的独立预测因素。
关键数值与推荐
- 全甲状腺切除指征:肿瘤大小>4cm、临床甲状腺外侵犯、临床淋巴结转移或远处转移。
- 需补充甲状腺切除定义为存在侵袭性组织学、甲状腺外侵犯、淋巴血管侵犯或非低危淋巴结转移。
临床怎么用
- 术前应告知适合腺叶切除的患者术后可能需补充甲状腺切除,并共同决策手术范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal extent of surgery for differentiated thyroid cancer may not be well recognized initially. Identification of intermediate-risk features on surgical pathology may prompt the need for completion thyroidectomy if a lobectomy is performed. In this study, we examined the factors in relation to the need for completion thyroidectomy. METHODS: We studied consecutive patients who underwent thyroidectomy for differentiated thyroid cancer from 2008 to 2017. Total thyroidectomy was indicated when tumor size >4 cm, clinical extrathyroidal extension, clinical lymph node metastasis, or distant metastasis was present. The need for completion thyroidectomy was defined as the presence of aggressive histology, extrathyroidal extension, lymphovascular invasion, or non-low-risk nodal metastasis. RESULTS: Among 771 patients, 155 (20%) were definitely indicated for total thyroidectomy. The need for completion thyroidectomy was identified in 273 (44%) of the 616 patients initially eligible for lobectomy. The proportions of patients requiring completion thyroidectomy were 18% and 57% for microcarcinomas and tumors of 1-4 cm, respectively. Receiver operating characteristic curve analysis indicated that tumor size ≥1.1 cm had the highest accuracy of prediction. Multivariate logistic regression revealed that tumor size and BRAF V600E mutation were independent factors predicting the risk of requiring completion thyroidectomy. CONCLUSION: A substantial portion of patients with differentiated thyroid cancer who are preoperatively eligible for lobectomy would be found to have intermediate-risk pathologic features. This should be incorporated into the shared decision making before surgery.
引用
- Cheng SP, Chien MN, Wang TY, et al. Reconsideration of tumor size threshold for total thyroidectomy in differentiated thyroid cancer. Surgery. 2018. PMID: 29843911. doi:10.1016/j.surg.2018.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。